Nautilus Biotechnology (NAUT) Amortizatization of Intangibles (2020 - 2026)
Nautilus Biotechnology's (NAUT) quarterly Amortizatization of Intangibles came in at $1.1 million in Q1 2026, up 111.09% year-on-year from $541000.0 in Q1 2025, and down 72.81% quarter-over-quarter from $4.2 million in Q4 2025.
Nautilus Biotechnology (NAUT) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has disclosed Amortizatization of Intangibles across 7 years of filings, most recently posting $1.1 million for Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $1.1 million, up 111.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (up 46.04% YoY), and the FY2025 annual result was $1.4 million, down 67.57% from the prior year.
- Amortizatization of Intangibles came in at $1.1 million for Q1 2026 at Nautilus Biotechnology, down from $4.2 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $4.2 million in Q4 2025 to a low of -$1.0 million in Q3 2025.
- The 5-year median for Amortizatization of Intangibles is $669000.0 (2023), against an average of $933176.5.
- Across the five-year window, Amortizatization of Intangibles soared 556.52% in 2022 and tumbled 6662.5% in 2025, its largest moves.
- Nautilus Biotechnology's Amortizatization of Intangibles stood at $1.9 million in 2022, then plunged by 66.7% to $619000.0 in 2023, then surged by 255.74% to $2.2 million in 2024, then soared by 90.74% to $4.2 million in 2025, then sank by 72.81% to $1.1 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $1.1 million (Q1 2026), $4.2 million (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nautilus Biotechnology | 289.99 Mn | 194.12 Mn | - | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.14 Mn |
| Mar 31, 2026 | 1.14 Mn |
| Dec 31, 2025 | 4.20 Mn |
| Dec 31, 2025 | 4.20 Mn |
| Sep 30, 2025 | -1.05 Mn |
| Sep 30, 2025 | -1.05 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 541,000.00 |
| Mar 31, 2025 | 541,000.00 |
| Dec 31, 2024 | 2.20 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 751,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Dec 31, 2023 | 619,000.00 |
| Dec 31, 2023 | 619,000.00 |